The debate on whether India should be allowed to become the ‘clinical trials hub’ of the world is slowly losing fire. When multinational companies zeroed-in on India about a decade back, critics called it their ploy to get “human guinea pigs” in India. Undoubtedly, India’s disease burden in cancer, diabetes and tuberculosis — far more than most countries — was the prime attraction. Add to that the huge population, cheaper operational costs, easy patient procurement, English speaking physicians and IPR preparedness — the perfect setting.

The country’s clinical trials market in 2006 was US$ 140m and is growing at a compounded annual rate of 40%. It is estimated to touch US$ 600m by 2010.

What’s your take on the clinical trials scenario in the country? Do you think India has overcome the initial setback of lack of experienced investigators and clinical research professionals? Is there better awareness of good clinical practice (GCP) compliance? Are ethics always in place?